These findings indicate a dynamic process of fluctuating of smaller clones during evolution and therapy in DLBCL that was marked by PIM1 and BCL2 mutations, suggesting that hypermutated genes may be useful to track clonal evolution. This evidence concerns the gene PIM1 and diffuse large B-cell lymphoma.